<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018261</url>
  </required_header>
  <id_info>
    <org_study_id>BST-LT-01</org_study_id>
    <nct_id>NCT04018261</nct_id>
  </id_info>
  <brief_title>Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients</brief_title>
  <official_title>A Prospective Multicenter Open-label, Not Controlled Phase Ib-II Clinical Trial to Assess the Safety and Immunologic Efficacy of Virus-specific T Lymphocytes From the Best Donor in Receptors of Hematopoietic Progenitor Allogeneic Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vall d'Hebron Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Fe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Marrow transplanted immunocompromised patients with cytomegalovirus (CMV) viral infection
      will be treated with CMV activated T-Lymphocytes. T-Lymphocytes will be obtained through an
      apheresis from a compatible donor.

      Safety and immunoreconstitution parameters in blood samples will be assessed up to +60 days
      after the treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multicentre, open-label and uncontrolled phase Ib-II clinical trial in which a
      total of 20 patients ≥ 1 year of age with an allogeneic transplant of hematopoietic
      progenitors and post-transplant CMV infection will be included. The main objective is to
      evaluate the safety of the infusion of CMV activated T-lymphocytes and secondary objectives
      are to evaluate the efficacy through clinical evolution, viral load, ability to induce
      immunoreconstitution against the virus and evaluation of the persistence of specific T cells.

      The treatment will be administered intravenously (central or peripheral route) in a single
      dose at a dose of 0.01-5 E4 specific virus T lymphocytes per Kg of receptor weight. After the
      infusion, patients will follow periodic controls (+7, +14, +21, +28, +45 and +60 days) in
      which a clinical evaluation will be performed and blood samples will be obtained in order to
      evaluate the persistence of specific T cells in the recipient:
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessment: Adverse events</measure>
    <time_frame>60 days</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Polymerase chain reaction (PCR)</measure>
    <time_frame>+7, +14, +21, +28, +45, +60 days</time_frame>
    <description>Quantitative viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IFN-γ+ spot forming cells</measure>
    <time_frame>+7, +14, +28, +60 days</time_frame>
    <description>Immune reconstitution by Elispot</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte subpopulations</measure>
    <time_frame>+7, +14, +28, +60 days</time_frame>
    <description>Immune reconstitution by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell persistence by chimerism</measure>
    <time_frame>+14, +28 days</time_frame>
    <description>Detection of donor cellularity (administered product) in the receptor serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time elapsed in identifying the donor</measure>
    <time_frame>Day 0</time_frame>
    <description>Time elapsed between the patient's inclusion in the trial and confirmation of the donor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>CMV Viremia</condition>
  <condition>Immunosuppression-related Infectious Disease</condition>
  <arm_group>
    <arm_group_label>Activated T-Lymphocytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic T-Lymphocytes obtained from apheresis activated against CMV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Activated T-Lymphocytes</intervention_name>
    <description>Activated T-Lymphocytes will be infused intravenously in a single-dose</description>
    <arm_group_label>Activated T-Lymphocytes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recipient of an allogeneic hematopoietic progenitors cell transplant (irrespectively
             of the donor source, donor type conditioning and underlying disease) that is beyond
             the day +30 of the procedure

          2. Patient with post-transplant infection due to CMV refractory or resistant to optimal
             pharmacological treatment. Specifically, the patient must be included in any of the
             following cases

               1. Patient with organic disease caused by CMV (confirmed by histology) resistant to
                  antiviral first line treatment

               2. Patient with CMV reactivation and no organic disease, resistant or intolerant to
                  2 previous antiviral treatment lines (ganciclovir/valganciclovir and foscarnet)
                  or not candidate to be treated due to not acceptable expected toxicity (severe
                  renal insufficiency, neutropenia or severe thrombopenia) It is agreed that the
                  patient is affected with a resistant CMV infection if the CMV copies doesn't
                  decrease in &gt; 1 log in total blood or otherwise the absolute number of copies &gt;
                  1x10E4/mL in total blood after 2 weeks of antiviral treatment.

               3. Patients with reactivation of recurrent CMV despite correct anti-CMV treatment.
                  It will be considered a recurrent CMV infection if the patient has &gt; 2
                  reactivations in a period &lt;6 months despite having received correct anti-CMV
                  treatment

               4. Documented genetic mutations associated with ganciclovir or foscarnet resistance

          3. ≥ 1 year of age

          4. Estimated life expectancy &gt; 30 days

          5. Signature of the informed consent form

        Exclusion Criteria:

          1. Acute graft-versus-host disease (GVHD) ≥ grade II or chronic ≥ moderate

          2. Corticosteroid ≥ 0.5mg/kg regardless the indication

          3. Disease relapse at the time of infection or at any time after the Allogeneic
             transplant.

          4. Severe renal disease (creatinine &gt; 3gr/dL)

          5. Severe hepatic disease (bilirubin &gt;3mg/dL or aspartate aminotransferase (AST) &gt;500
             U/L) except if it is secondary to the viral infection.

          6. Having received a donor lymphocytes infusion or any cell therapy product within 60
             days prior to inclusion in the study (with the exception of transfusions), or having
             it planned within the next 60 days.

          7. Alteration of the general condition, infection or clinical or hemodynamic instability
             that, in the opinion of the researcher, does not recommend the use of T cells

          8. Known hypersensitivity to murine proteins or iron dextran.

          9. Positive serology to human immunodeficiency virus (HIV), hepatitis B virus (HBV)
             (HBsAg, HBcAc), hepatitis C virus (HCV) and/or syphilis

         10. Pregnant, lactating or women without adequate contraception

         11. Participation in a clinical trial with investigational medicinal products the last 30
             days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere Barba, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VHIO (Vall d'Hebron Institute of Oncology)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth Coll, MD</last_name>
    <phone>+34935573500</phone>
    <phone_ext>6707</phone_ext>
    <email>rucoll@bst.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Ferrá, MD, PhD</last_name>
      <phone>+34 934651200</phone>
      <email>cferra@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Christelle Ferrá, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Júlia Marsal, MD, PhD</last_name>
      <phone>+34 932532100</phone>
      <email>jmarsal@sjdhospitalbarcelona.org</email>
    </contact>
    <investigator>
      <last_name>Júlia Marsal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Izaskun Elorza Elorza, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO l'Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Parody, MD, PhD</last_name>
      <phone>+34 932607733</phone>
      <email>rparody@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Rocio Parody, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodrigo Martino, MD, PhD</last_name>
      <phone>+34 935565649</phone>
      <email>RMartino@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Rodrigo Martino, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Barba, MD, PhD</last_name>
      <phone>+34 934893000</phone>
      <email>pbarba@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Pere Barba, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Alonso, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillermo Ortí, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Rovira, MD, PhD</last_name>
      <phone>+34 932275400</phone>
      <email>mrovira@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Montserrat Rovira, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Montoro, MD</last_name>
      <phone>+34 961244000</phone>
      <email>juanmontorogomez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Montoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Guerreiro, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bancsang.net</url>
    <description>Blood and Tissue Bank of Catalonia</description>
  </link>
  <link>
    <url>http://www.vhio.net</url>
    <description>Vall d'Hebron Institute of Oncology</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMV</keyword>
  <keyword>Bone marrow transplant</keyword>
  <keyword>Activated T-Lymphocytes</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Virus infection</keyword>
  <keyword>immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

